2011
DOI: 10.1007/s11096-011-9571-5
|View full text |Cite
|
Sign up to set email alerts
|

Cefepime-associated thrombocytopenia in a critically ill patient

Abstract: Although cefepime-induced thrombocytopenia is rare, clinicians should be alert to this potential adverse effect among critically ill patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
18
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(18 citation statements)
references
References 8 publications
(22 reference statements)
0
18
0
Order By: Relevance
“…It is important to note that despite the pan-sensitivity of our patient's organism, we deemed it medically prudent to change antibiotics, and discontinue antifungal and antiviral therapy due to the patient's persistent thrombocytopenia and overall low risk for viral and fungal pathogens. Reports have found correlations between antibacterial, antifungal, and antiviral medications causing thrombocytopenia, including cefepime, fluconazole, and valaciclovir [8][9][10].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…It is important to note that despite the pan-sensitivity of our patient's organism, we deemed it medically prudent to change antibiotics, and discontinue antifungal and antiviral therapy due to the patient's persistent thrombocytopenia and overall low risk for viral and fungal pathogens. Reports have found correlations between antibacterial, antifungal, and antiviral medications causing thrombocytopenia, including cefepime, fluconazole, and valaciclovir [8][9][10].…”
Section: Discussionmentioning
confidence: 99%
“…Blood cultures returned negative. Due to our patient's low risk for complication as determined by her Multinational Association for Supportive Care in Cancer (MASCC) score of 24, and Clinical Index of Stable Febrile Neutropenia (CISNE) score of 1, cefepime, valaciclovir, and fluconazole were discontinued due to their potential to decrease platelets, and ceftriaxone was started instead and continued for 4 more days [8][9][10]. WBCs dropped again between days 5 through 7, and platelets decreased between days 7 and 8.…”
Section: Case Presentationmentioning
confidence: 99%
“…A ceftazidime-induced thrombocytopenia case of an adult patient was reported for the first time in the Spanish pharmacovigilance system ( Domingo-Chiva et al, 2017 ). Similarly, there is limited post-marketing surveillance evidence on thrombocytopenia associated with cefepime and ceftizoxime sodium ( Lim et al, 2011 ). Because a delay in recognition can lead to significant morbidity and mortality, clinical criteria such as the Naranjo Adverse Drug Reaction Probability Scale were used to help determine the risk of DITP, which were less efficient.…”
Section: Discussionmentioning
confidence: 99%
“…Other adverse effects are found in a few case reports: acute renal failure [ 185 ] and electrolyte disorders [ 186 ]; severe intravascular haemolysis [ 187 , 188 ]; extreme thrombocytosis [ 189 ]; severe thrombocytopenia [ 190 193 ]; leukopenia [ 194 ]; delayed-type hypersensitivity [ 195 ]; anaphylactic shock [ 196 ]; and severe cutaneous reactions [ 197 ].…”
Section: Toxicitymentioning
confidence: 99%